PL1845966T3 - Farmaceutyczny preparat do zastosowania w leczeniu lub profilaktyce chorób nowotworowych - Google Patents

Farmaceutyczny preparat do zastosowania w leczeniu lub profilaktyce chorób nowotworowych

Info

Publication number: PL1845966T3
Authority: PL; Poland
Prior art keywords: prophylaxis; treatment; glutamine; pharmaceutical preparation; alpha
Prior art date: 2005-01-11

Application number

PL06700207T

Other languages

English (en)

Inventor

Stephan Pyerzynowski

Martyna Kandefer-Szerszeń

Wojciech Rzeski

Original Assignee

Sgp & Sons Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-01-11

Filing date

2006-01-10

Publication date

2011-02-28

2006-01-10 Application filed by Sgp & Sons Ab filed Critical Sgp & Sons Ab

2011-02-28 Publication of PL1845966T3 publication Critical patent/PL1845966T3/pl

Links

201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
230000001613 neoplastic effect Effects 0.000 title 1
239000000825 pharmaceutical preparation Substances 0.000 title 1
238000011321 prophylaxis Methods 0.000 title 1
238000011282 treatment Methods 0.000 title 1
KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 abstract 5
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 4
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 3
150000001413 amino acids Chemical class 0.000 abstract 3
229930195712 glutamate Natural products 0.000 abstract 3
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 abstract 2
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 abstract 2
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 abstract 2
229960003104 ornithine Drugs 0.000 abstract 2
108010016626 Dipeptides Proteins 0.000 abstract 1
230000000118 anti-neoplastic effect Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
239000002184 metal Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)

PL06700207T 2005-01-11 2006-01-10 Farmaceutyczny preparat do zastosowania w leczeniu lub profilaktyce chorób nowotworowych PL1845966T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PL372183A PL372183A1 (pl)	2005-01-11	2005-01-11	Preparat przeciwnowotworowy oraz zastosowanie preparatu przeciwnowotworowego
PCT/PL2006/000003 WO2006075924A1 (en)	2005-01-11	2006-01-10	Antineoplastic preparation and the use of antineoplastic preparation
EP06700207A EP1845966B1 (en)	2005-01-11	2006-01-10	Pharmaceutical preparation for use in the treatment or prophylaxis of neoplastic diseases

Publications (1)

Publication Number	Publication Date
PL1845966T3 true PL1845966T3 (pl)	2011-02-28

Family

ID=36168380

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL372183A PL372183A1 (pl)	2005-01-11	2005-01-11	Preparat przeciwnowotworowy oraz zastosowanie preparatu przeciwnowotworowego
PL06700207T PL1845966T3 (pl)	2005-01-11	2006-01-10	Farmaceutyczny preparat do zastosowania w leczeniu lub profilaktyce chorób nowotworowych

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL372183A PL372183A1 (pl)	2005-01-11	2005-01-11	Preparat przeciwnowotworowy oraz zastosowanie preparatu przeciwnowotworowego

Country Status (12)

Country	Link
US (1)	US7759396B2 (pl)
EP (1)	EP1845966B1 (pl)
JP (2)	JP2008526838A (pl)
CN (1)	CN101111241B (pl)
AT (1)	ATE474570T1 (pl)
AU (1)	AU2006205279B2 (pl)
CA (1)	CA2593780C (pl)
DE (1)	DE602006015608D1 (pl)
DK (1)	DK1845966T3 (pl)
ES (1)	ES2349233T3 (pl)
PL (2)	PL372183A1 (pl)
WO (1)	WO2006075924A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2033623A1 (en)	2007-09-07	2009-03-11	Cutech S.R.L.	Compositions comprising ornithine ketoglutarate (OKG)
CN113082009A (zh) *	2014-02-12	2021-07-09	加利福尼亚大学董事会	用于治疗衰老和与年龄相关的疾病和症状的组合物和方法
WO2025263592A1 (ja) *	2024-06-19	2025-12-26	Ａｇｃ株式会社	グルタミン代謝阻害剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT393221B (de) *	1988-02-03	1991-09-10	Leopold Pharma Gmbh	Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken
FR2775901B1 (fr) *	1998-03-13	2000-07-21	Logeais Labor Jacques	Sels de cetoacides et de derives amines, et leur utilisation pour la preparation de medicaments
SE0201713D0 (sv) *	2001-11-23	2002-06-06	Gramineer Internat Ab	New methods and use III
NZ538405A (en)	2002-08-01	2007-12-21	Aesgen Inc	Improved treatment of cancer with glutamine and carbohydrate
AT412447B (de) *	2002-11-27	2005-03-25	C Y L Handelsges M B H	Mittel mit zerstörender wirkung auf maligne tumore sowie verfahren zu seiner herstellung
PT1534305E (pt) *	2003-05-07	2007-02-28	Osteologix As	Tratamento de afecções cartilagineas / osseas com sais de estroncio hidrosoluveis
US20050124684A1 (en) *	2003-08-29	2005-06-09	Ying Du	5-(hydroxymethyl) furfural and derivatives as inhibitors of TNFalpha and IL-1beta production
ES2510690T3 (es)	2004-12-17	2014-10-21	Alan B. Cash	Método para extender la esperanza de vida y retrasar la aparición de enfermedad relacionada con la edad

2005
- 2005-01-11 PL PL372183A patent/PL372183A1/pl not_active Application Discontinuation
2006
- 2006-01-10 EP EP06700207A patent/EP1845966B1/en not_active Expired - Lifetime
- 2006-01-10 DE DE602006015608T patent/DE602006015608D1/de not_active Expired - Lifetime
- 2006-01-10 DK DK06700207.1T patent/DK1845966T3/da active
- 2006-01-10 US US11/813,526 patent/US7759396B2/en not_active Expired - Fee Related
- 2006-01-10 AT AT06700207T patent/ATE474570T1/de not_active IP Right Cessation
- 2006-01-10 CA CA2593780A patent/CA2593780C/en not_active Expired - Fee Related
- 2006-01-10 AU AU2006205279A patent/AU2006205279B2/en not_active Ceased
- 2006-01-10 JP JP2007550321A patent/JP2008526838A/ja not_active Ceased
- 2006-01-10 ES ES06700207T patent/ES2349233T3/es not_active Expired - Lifetime
- 2006-01-10 WO PCT/PL2006/000003 patent/WO2006075924A1/en not_active Ceased
- 2006-01-10 CN CN2006800019675A patent/CN101111241B/zh not_active Expired - Fee Related
- 2006-01-10 PL PL06700207T patent/PL1845966T3/pl unknown
2012
- 2012-10-01 JP JP2012219701A patent/JP2013035864A/ja active Pending

Also Published As

Publication number	Publication date
AU2006205279A1 (en)	2006-07-20
US7759396B2 (en)	2010-07-20
CN101111241B (zh)	2010-12-01
CA2593780A1 (en)	2006-07-20
WO2006075924A1 (en)	2006-07-20
PL372183A1 (pl)	2006-07-24
CA2593780C (en)	2013-11-26
US20080058422A1 (en)	2008-03-06
JP2013035864A (ja)	2013-02-21
ATE474570T1 (de)	2010-08-15
ES2349233T3 (es)	2010-12-29
CN101111241A (zh)	2008-01-23
AU2006205279B2 (en)	2011-05-26
EP1845966B1 (en)	2010-07-21
DK1845966T3 (da)	2010-11-08
JP2008526838A (ja)	2008-07-24
EP1845966A1 (en)	2007-10-24
DE602006015608D1 (de)	2010-09-02

Similar Documents

Publication	Publication Date	Title
TNSN07452A1 (en)	2009-03-17	Stabile active ingredient complex of salts of the o-acetylsalicylic acid with basic amino acids and glycine
MX341883B (es)	2016-09-07	Composicion farmaceutica para el tratamiento y prevencion de canceres.
ZA200707508B (en)	2008-12-31	2-[isoquinolin-3-carbonyl) amino] -propionic acid derivatives as inhibitors of factors XI and IX for the treatment of thrombosis
TW200634051A (en)	2006-10-01	Processes for preparing a polypeptide
WO2011107653A3 (en)	2011-11-03	Use of levodopa, carbidopa and entacapone for treating parkinson's disease
AU2008267058A8 (en)	2013-03-14	Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
EP2584043A3 (en)	2013-10-02	Anti-glypican 3 antibody having improved kinetics in plasma
IL185031A0 (en)	2007-12-03	Method for the preparation of pregabalin and salts thereof
WO2006128058A3 (en)	2007-05-10	Thyromimetics for the treatment of fatty liver diseases
WO2008053297A3 (en)	2009-04-23	Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
MX2008014273A (es)	2009-05-11	Procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion.
MXPA05014082A (es)	2006-03-02	Acidos biariloximetilarenocarboxilicos.
WO2008021463A3 (en)	2008-12-24	Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
WO2006062424A3 (en)	2007-02-15	Use of 3-hydroxy-3-methylbutyrate alone or in combination with alpha-ketoglutarate in the growth and mineralisation of the osteo-skeletal system
WO2007053390A3 (en)	2007-08-09	Methods for the use of branched chain amino acids
TNSN07228A1 (en)	2008-11-21	Manufacture process of organic compounds
WO2007000001A3 (en)	2007-03-08	Pleuromutilin salts with salicylic acid, azelaic acid, sebacic acid and diclofenac
UA90893C2 (ru)	2010-06-10	Пероральная дозированная форма производных гемцитабина
DK1845966T3 (da)	2010-11-08	Farmaceutisk sammensætning til anvendelse i behandlingen eller forebyggelsen af neoplastiske sygdomme
TW200612922A (en)	2006-05-01	Inhibitors of hsp90
MXPA05006408A (es)	2006-03-08	Derivados deuterizados de catecolamina y medicamentos comprendiendo estos compuestos.
UA94042C2 (ru)	2011-04-11	Применение агомелатина в получении лекарственных средств, предназначенных для лечения синдрома смита-магениса
UA83900C2 (en)	2008-08-26	Amorphous forms of risedronate monosodium
MX2022001076A (es)	2022-04-26	Metodo para tratar la enfermedad de alzheimer mediante la inhibicion de la captacion de aminoacidos por las celulas t.
EP1806983B8 (en)	2009-02-18	Nutritional and/or pharmaceutical preparation for use in prophylaxis and treatment of disturbances in microelements absorption from the alimentary canal